Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity
By Aditya Bhagchandani Published on June 18, 2025, 16:48 IST
Zydus Lifesciences Ltd has announced the successful conclusion of a Good Manufacturing Practices (GMP) follow-up inspection by the United States Food and Drug Administration (USFDA) at its oncology injectable manufacturing facility located at SEZ 1, near Matoda, Ahmedabad. The inspection was conducted over a 10-day period, from June 9 to June 18, 2025.
In a regulatory filing to the stock exchanges, the company stated, 'We wish to inform that the US Food and Drug Administration (USFDA) conducted a GMP follow-up inspection at the company's oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad.'
The company further added that the inspection concluded with two observations, emphasizing that 'none of them were related to data integrity.' Zydus assured stakeholders that it is taking these observations seriously and is committed to addressing them promptly.
'The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner,' the statement read.
This update has been provided in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Zydus also requested that this development be 'brought to the notice of the members of the exchange and the investors at large.'
The successful closure of the inspection without any data integrity issues is a positive sign for Zydus, reaffirming its compliance with global manufacturing standards in a critical therapeutic segment.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
14 hours ago
- Fox News
Business Rundown: Apple Facing 'Stringent Regulations' Abroad
iPhone maker Apple found itself in the crosshairs of the EU's antitrust regulators this week. Now the company faces an ultimatum: comply with their rules for Big Tech or face serious fines. FOX Business co-anchor of The Big Money Show Taylor Riggs speaks with Senior Tech Fellow at the Center for European Policy Analysis, Enrique, about the business conditions for big American tech companies in Europe, Apple's choices moving forward, and how the EU's stringent regulations have stifled innovation. Photo Credit: AP Learn more about your ad choices. Visit
Business Upturn
a day ago
- Business Upturn
Aarvi Encon secures twin manpower contracts worth over Rs 30 crore
By Aditya Bhagchandani Published on June 20, 2025, 16:40 IST Aarvi Encon Limited has announced the receipt of two significant work orders from a leading multinational EPC company, with a combined value exceeding Rs 30.67 crore. As per the company's regulatory filings, the first contract is worth Rs 22.53 crore and entails supplying manpower on an outsourcing basis to various project sites and offices across India. This contract is valid for two years starting June 3, 2025, and will continue until June 4, 2027. In addition to this, Aarvi Encon has secured a second contract valued at Rs 8.13 crore. This one-year agreement, effective from July 1, 2025, involves similar manpower supply services at multiple domestic locations. Both contracts are with the same unnamed domestic entity and fall under non-related party transactions. The company has signed a Non-Disclosure Agreement, and therefore, the client's identity remains confidential. These orders bolster Aarvi Encon's pipeline and reaffirm its positioning in India's engineering staffing and outsourcing segment. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
a day ago
- Business Upturn
Granules India's Bonthapally facility completes US FDA inspection with one observation
By Aditya Bhagchandani Published on June 20, 2025, 16:28 IST Granules India announced on June 20, 2025, that its API Unit-I facility at Bonthapally, located in Sangareddy District near Hyderabad, has successfully completed a US FDA inspection conducted between June 16 and June 20. The inspection concluded with a single Form 483 observation. In an exchange filing, the company stated it would address the observation within the prescribed timeline. Granules emphasized that the Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing units by volume and also houses manufacturing plants for Metformin and Guaifenesin APIs. The company assured investors that the outcome will be managed in line with regulatory expectations. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
